SynAct Pharma AB (publ) announced it will introduce the generic name resomelagon for its lead candidate AP1189, a unbiased melanocortin receptor agonist developed for treatment of active inflammatory and autoimmune diseases. Resomelagon was recently included by the World Health Organization (WHO) on list 89 of recommended International Nonproprietary Names (INN), to denote the structure of the active part of AP1189. The INN expert group at WHO has agreed to use the suffix "melagon" for designation of the non-peptidic melanocortin 1 and 3 agonists.

The prefix "reso", specific to AP1189, is referring to its effect on resolution of inflammation. List 89 of recommended INN, including resomelagon, will be published in WHO Drug Information, Vol 37, No 1, 2023. According to the WHO, INNs facilitate the identification of pharmaceutical substances or active pharmaceutical ingredients.

Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.